Trial Questions Role of Dual Immunotherapy in First-Line NSCLC

Published Date: 26 Aug 2024

In Japanese trial, nivolumab-ipilimumab didn't improve OS versus pembrolizumab, had more toxicity

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

PET-CT finds further-reaching metastases in patients with locally advanced breast cancer.

2.

Pancreatic cancer RNA vaccine shows durable T cell immunity

3.

Patients value communication skills from cancer surgeons across six key areas, according to research

4.

Why Did Rare Cancer Shrink on Its Own?

5.

Two medications might work better for breast cancers that are resistant to one.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot